Vaccine will take Pfe stock to 70.

Discussion in 'Pfizer' started by anonymous, Jan 27, 2021 at 10:01 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    During the 90s, Pfizer stock split three times. One of those was a 3 for 1. Overweighting Pfizer in your 401k was a valuable thing if you had no immediate plans to retire. Today, Pfizr has no chance of such a growth rate.
     

  2. anonymous

    anonymous Guest

    Last 90 days the stock went from 42 to 34.
    Going wrong direction and will never ever hit 90 in 100yrs.
    Pfe is worse investment for stocks.
     
  3. anonymous

    anonymous Guest

    The stock will finds its way lower....and staffing reduced further.

    The FDA already has restrictions on the use of Pfizer’s JAK inhibitor Xeljanz at a higher dose because of safety concerns. Now, thanks to new red flags, the agency is weighing a move to tighten those restrictions.

    In a post Thursday, the=>=> FDA alerted patients and doctors that a postmarket study has linked Xeljanz to an increased risk of serious heart-related problems and cancer compared with TNF inhibitors, a group that includes such drugs as AbbVie’s Humira. The **=>>problems applied to both the 5-mg twice-daily dose and the higher 10-mg strength.

    The agency said it’ll evaluate the clinical trial results and consider what moves to take. The **last time it made that kind of comment, it wound up putting a boxed warning on the high dose and stripping it of its use in previously untreated ulcerative colitis.
     
  4. anonymous

    anonymous Guest

    Xeljanz will stop that fantasy
     
  5. anonymous

    anonymous Guest

    Pfizer’s stock and performance is a joke. If any territory rep at Pfizer had the same performance, they would be shit canned.
     
  6. anonymous

    anonymous Guest

    This is so true. LOL

    PFE will see sub 30 before it even comes close to 40 by 2023. Dog w/ Fleas.... all the while as you see Management posting on Linked-In how wonderful PFE is... Can't even call this a Dividend play anymore since the stock goes down more than anything else. Bloated Director level and up Company that needs a total gut job and rethinking of it's business model.